167 related articles for article (PubMed ID: 33227304)
21. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
22. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K; Carlsson SV; Roobol MJ
Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
[TBL] [Abstract][Full Text] [Related]
23. Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer.
Nyame YA; Gulati R; Tsodikov A; Gore JL; Etzioni R
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442662
[TBL] [Abstract][Full Text] [Related]
24. Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
Hu JC; Nanus DM; Sedrakyan A
Eur Urol; 2017 Jan; 71(1):147-149. PubMed ID: 27402061
[No Abstract] [Full Text] [Related]
25. Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
Plambeck BD; Wang LL; Mcgirr S; Jiang J; Van Leeuwen BJ; Lagrange CA; Boyle SL
Prostate; 2022 Feb; 82(2):216-220. PubMed ID: 34807485
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
27. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.
Dalela D; Sun M; Diaz M; Karabon P; Seisen T; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2019 Jan; 5(1):77-80. PubMed ID: 28753893
[TBL] [Abstract][Full Text] [Related]
28. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.
C J; Y P; Sf B; Rj B
Cancer Treat Res Commun; 2021; 26():100225. PubMed ID: 33360667
[TBL] [Abstract][Full Text] [Related]
29. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
[TBL] [Abstract][Full Text] [Related]
32. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
33. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
[TBL] [Abstract][Full Text] [Related]
34. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
[TBL] [Abstract][Full Text] [Related]
35. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
36. Grade Migration of Prostate Cancer in the United States During the Last Decade.
Borregales LD; DeMeo G; Gu X; Cheng E; Dudley V; Schaeffer EM; Nagar H; Carlsson S; Vickers A; Hu JC
J Natl Cancer Inst; 2022 Jul; 114(7):1012-1019. PubMed ID: 35348709
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
38. PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
Magnani CJ; Li K; Seto T; McDonald KM; Blayney DW; Brooks JD; Hernandez-Boussard T
J Natl Compr Canc Netw; 2019 Jul; 17(7):795-803. PubMed ID: 31319390
[TBL] [Abstract][Full Text] [Related]
39. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
[TBL] [Abstract][Full Text] [Related]
40. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
Jemal A; Culp MB; Ma J; Islami F; Fedewa SA
J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
